| ID | 1169 |
| Name of the vaccine | LEP-F1 + GLA-SE |
| Microbe | Bacteria |
| Disease name | Leprosy |
| Name of bacteria | Mycobacterium leprae |
| Type of vaccine | Subunit |
| Nucleic acid content | DNA |
| Age | 18 to 55 years |
| Description of the vaccine | Recombinant four-antigen Mycobacterium leprae antigen LEP-F1 in combination with the adjuvant formulation GLA-SE. |
| Name of the manufacturer | IDRI |
| Name of the manufacturing country | Brazil |
| Year of manufacture | 2021 |
| Clinical Phase status | Clinical - Withdrawn |
| Bacterial strain | Acid fast gram-positive bacteria. |
| Efficacy | NA |
| Vaccine formulation | Suspension for injection |
| Dosage | Three doses on days 0, 28, and 56. |
| Mechanism of action | LEP-F1-specific IgG antibodies and generated LEP-F1-specific Th1 cells. |
| Route of administration | Intramuscular |
| Indications | Prevention of leprosy. |
| Export | NA |
| Approval | NA |
| Adjuvant | GLA-SE |
| Repurposing | NA |
| Side effects of vaccine | Pain, erythema, induration, headache, arthralgia, chills, loss of appetite, fever, fatigue and myalgia. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | 31899025 |
| Clinical trial number | NCT03947437 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|